Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. (22nd February 2021)

• Record Type: Journal Article
• Authors: Pezel, Theo; Audureau, Etienne; Mansourati, Jacques; Baudry, Guillaume; Ben Driss, Ahmed; Durup, Florence; Fertin, Marie; Godreuil, Christian; Jeanneteau, Julien; Kloeckner, Martin; Koukoui, François; Kesri‐Tartière, Lamia; Laperche, Thierry; Roubille, François; Cohen‐Solal, Alain; Damy, Thibaud
• Is Part Of: ESC heart failure. Volume 8:Number 2(2021)
• Page Start: 1509
• Page End: 1521
• Publication Date: 2021-02-22
• Subjects: Heart failure -- Iron deficiency -- Iron supplementation -- Diagnosis -- Guidelines; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13245
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Iron deficiency (ID) occurs in about 50% of patients with heart failure (HF). The European Society of Cardiology (ESC) recommends ID diagnostic testing in newly diagnosed patients with HF and during follow‐up, with intravenous iron supplementation (IS) only recommended in patients with HF with reduced ejection fraction (HFrEF). This study aimed to assess prevalence, clinical characteristics, and application of ESC guidelines for ID and IS in patients with HF in the real‐life clinical setting. Methods and results: The French transversal multicentre OFICSel registry (300 cardiologists) conducted in 2017 included patients hospitalized for HF at least once in the previous 5 years. Diverse adult patients were eligible including inpatients and outpatients and those with acute and chronic HF. Data were collected from cardiologists and patients using study‐specific surveys. Data included demographic and clinical data, as well as HF and ID management data. Overall, 2822 patients, mainly male (69.3%) with a median age of 69 years (interquartile range 58–78), were included. A total of 1075 patients (38.1%) were tested for ID, with 364 (33.9%) diagnosed. Of these, 168 (46.2%) received IS: 128 (76.2%) intravenous IS and 40 (23.8%) oral. Among the 201 patients with HFrEF diagnosed with ID, 99 (49.3%) received IS: 79 (79.8%) intravenous IS and 20 (20.2%) oral. Conclusions: In clinical practice, only one‐third of patients with HF had a diagnostic test for ID. In patients with ID with HFrEF, only 39.3% received intravenous IS as recommended. Thus, in general, cardiologists should be encouraged to follow the ESC guidelines to ensure optimal treatment for patients with HF.